Drug-induced liver injury: the dawn of biomarkers? - Wikidata - wikimedia - TriplyDB

Drug-induced liver injury: the dawn of biomarkers?

Drug-induced liver injury: the dawn of biomarkers?

http://www.wikidata.org/entity/Q35210890

about

From hepatoprotection models to new therapeutic modalities for treating liver diseases: a personal perspective Clinical decision support for drug related events: Moving towards better prevention Drug-induced liver injury: recent advances in diagnosis and risk assessment.Current Biochemical Monitoring and Risk Management of Immunosuppressive Therapy after Transplantation Revisiting the Metabolism and Bioactivation of Ketoconazole in Human and Mouse Using Liquid Chromatography-Mass Spectrometry-Based Metabolomics.Drug-induced liver injury: Do we know everything?Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature.Defining baseline epigenetic landscapes in the rat liver.Modulation of miR-26a-5p and miR-15b-5p Exosomal Expression Associated with Clopidogrel-Induced Hepatotoxicity in HepG2 Cells.Current trends in in silico, in vitro toxicology, and safety biomarkers in early drug development.Assessment of Preclinical Liver and Skeletal Muscle Biomarkers Following Clofibrate Administration in Wistar Rats.

P2860

Q26738626-A6588529-F2D9-4055-884E-E85C0A9478F6 Q28067548-1EE777AE-AA25-40B8-8A3E-313B79358459 Q30235089-BE23C70A-D867-4C99-8575-3C801BC41542 Q33801096-C003FDD6-A920-49C5-813C-485DD28BF842 Q37729280-8E4C15CF-D0FA-4649-A14F-C1FEF135D751 Q37748005-F1428EF3-5DB5-4E22-BE7B-F18FAA7E81D0 Q38824550-A7DBB04D-9183-44BC-B98D-CC4457F59A5F Q46262957-5FE02660-A495-455B-BF8E-F75D08F84DD3 Q47335450-9B99D0C0-0886-4711-BB27-5A5FFACB6DF3 Q47434464-4AF4CA88-748D-4230-8E92-89B5F735A414 Q50645749-09DD254B-5705-413C-BC0B-6B5A3A33F990

P2860

Drug-induced liver injury: the dawn of biomarkers?

http://www.wikidata.org/entity/Q35210890

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Drug-induced liver injury: the dawn of biomarkers?

@ast

Drug-induced liver injury: the dawn of biomarkers?

@en

type

label

Drug-induced liver injury: the dawn of biomarkers?

@ast

Drug-induced liver injury: the dawn of biomarkers?

@en

prefLabel

Drug-induced liver injury: the dawn of biomarkers?

@ast

Drug-induced liver injury: the dawn of biomarkers?

@en

P1433

Q35210890-275449C0-6432-4947-8688-B9E1D7C4D2EB

P1476

Q35210890-1D0FB2DF-BAD2-4FF1-91EE-8590BE46E660

P2093

Q35210890-12C23408-AEAB-4D42-8DEC-237D924B2839

Q35210890-75C9846A-3B1E-4C8A-82CA-F6CD02A3E2C8

Q35210890-C49C2F4E-8F96-4236-A443-D90D79708266

P2860

Q35210890-0398AB8B-B192-45DF-94BC-F31888DED571

Q35210890-0412DB79-9F71-4E04-ADFF-46460F64BC6C

Q35210890-0D4987C5-7FBC-4F64-A932-F23B4811591A

Q35210890-1CE74F98-5D69-46B0-BDFB-54AEB80EAB95

Q35210890-1D13C0C7-9B83-4D88-BF88-D94DCD6934E7

Q35210890-2B888781-CAC1-4BA2-89D3-47FEED35A416

Q35210890-333B828F-2809-445F-A673-AE552D3C8827

Q35210890-379BD4EA-3FF4-4D01-93E6-9389D4F7B73A

Q35210890-3EECDF58-07F0-478A-8BB4-2A43FFFEE2DD

Q35210890-54002830-A163-48BB-B565-A045EF0360AF

P304

Q35210890-FB5F88D8-EBB0-4A10-A0D1-1A3D9E6239D1

P31

Q35210890-E9A8A300-68CB-4F9B-AF0C-8ADE221BBED8

P356

Q35210890-90DECBBC-8311-4A6E-A173-757CF80A5574

P478

Q35210890-937EB215-ABA3-41E1-BB81-C937995D2FE8

P577

Q35210890-D966CB63-CEFD-484B-A80C-8FAC36B39E10

P698

Q35210890-2B7D0998-DFBE-4F17-83BE-54E11960E1A4

P921

Q35210890-866FE0E5-8969-4A47-AB01-A59340B94CE4

P932

Q35210890-8209F7B2-C716-4E0E-A992-B6B26D16716E

P356

P1433

F1000prime reports

P1476

Drug-induced liver injury: the dawn of biomarkers?

@en

P2093

Gerd A Kullak-Ublick

http://www.w3.org/2001/XMLSchema#string

Michael Merz

http://www.w3.org/2001/XMLSchema#string

Stefan Weiler

http://www.w3.org/2001/XMLSchema#string

P2860

Liver safety assessment in special populations (hepatitis B, C, and oncology trials)

Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.

Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells.

Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome.

Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges.

Drug-related hepatotoxicity.

HLA-B*5701 screening for hypersensitivity to abacavir.

P304

34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12703/P7-34

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25926985

http://www.w3.org/2001/XMLSchema#string

P921

P932

4371234

http://www.w3.org/2001/XMLSchema#string